|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral capsule
|
|
gptkbp:approves
|
gptkb:2007
|
|
gptkbp:atccode
|
N06 BA12
|
|
gptkbp:brand
|
gptkb:Vyvanse
|
|
gptkbp:casnumber
|
608137-41-9
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C15 H22 N2 O3 S
|
|
gptkbp:class
|
gptkb:pharmaceuticals
|
|
gptkbp:clinical_trial
|
ADHD treatment studies
binge eating disorder studies
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
hyperthyroidism
history of drug abuse
cardiovascular disorders
|
|
gptkbp:dosage_form
|
gptkb:capsule
chewable tablet
|
|
gptkbp:effective_date
|
2007-02-23
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lisdexamfetamine dimesylate
|
|
gptkbp:ingredients
|
gptkb:lisdexamfetamine
|
|
gptkbp:interacts_with
|
MAO inhibitors
antihypertensives
acidifying agents
alkalinizing agents
|
|
gptkbp:legal_status
|
controlled substance
|
|
gptkbp:lifespan
|
10-13 hours
|
|
gptkbp:manufacturer
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:maximum_dose
|
70 mg
|
|
gptkbp:mechanism_of_action
|
increases dopamine and norepinephrine levels
|
|
gptkbp:metabolism
|
gptkb:dextroamphetamine
|
|
gptkbp:pharmacokinetics
|
prodrug
CNS stimulant
|
|
gptkbp:related_to
|
gptkb:amphetamine
gptkb:dextroamphetamine
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
anxiety
nausea
irritability
insomnia
dry mouth
loss of appetite
|
|
gptkbp:starting_dose
|
30 mg
|
|
gptkbp:structure
|
dimesylate salt
|
|
gptkbp:used_for
|
treatment of ADHD
treatment of binge eating disorder
|
|
gptkbp:bfsParent
|
gptkb:Lisdexamfetamine
|
|
gptkbp:bfsLayer
|
6
|